Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1
week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR
use among women either with BV or at high risk for BV. The investigators will also recruit
women who are HSV2-infected.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)